2 Healthcare Stocks Analysts Call "Buys"

Piper Jaffray is bullish on MYGN's GeneSight genetic test

Oct 10, 2018 at 2:00 PM
facebook twitter linkedin


Stocks are getting hammered today, with the tech sector leading the pullback. Three healthcare names making big moves are Myriad Genetics, Inc. (NASDAQ:MYGN), Ra Pharmaceuticals, Inc. (NASDAQ:RARX), and AcelRx Pharmaceuticals Inc (NASDAQ:ACRX). Check out what's happening with shares of MYGN, RARX, and ACRX below.

MYGN Gets Bull Note From Piper Jaffray

MYGN shares are trading up 7.1% at $46.26, jumping above recent resistance from the 20-day moving average, thanks to a price-target lift to $54 from $51 at Morgan Stanley and a bullish call out of Piper Jaffray. The latter brokerage firm lifted its rating on the diagnostics name to "overweight" from "neutral" and set a $53 price target, saying the company's GeneSight genetic test could increase revenue by $400 million. The stock has been a strong gainer since early May, when it was trading right around $28, and sports a year-to-date advance of almost 35%.

Meanwhile, short-term options traders have been extremely put-skewed on Myriad Genetics. This is according to its Schaeffer's put/call open interest ratio (SOIR) of 1.83, which ranks in the 96th annual percentile.

RARX Stock Pullback Comes to a Halt

RARX stock is up 7.8% to trade at $15.74, after a "strong buy" recommendation from Raymond James. The analyst note, which noted a price target of $28, cited potentially strong data from the company's C5 inhibitor, zilucoplan, due out later this year.

Today's spike puts an end to the shares' precipitous decline since the Oct. 1 high of $19.43, trading back near their year-over-year breakeven point. Analysts are somewhat bullish on the drugmaker, with an average 12-month price target of $22.17.

FDA Report Gives AcelRx Pharmaceuticals a Boost

ACRX stock is up 30% at $3.44, after the Food and Drug Administration (FDA) said the company's opioid painkiller could be used in hospitals. This prompted Ladenburg Thalmann to raise its price target to $10 from $7 -- territory not seen since 2014. Looking closer, AcelRx Pharmaceuticals' peak today occurred near its 20-day moving average. Sentiment on the security remains mostly upbeat, with four of six analysts sporting "buy" or "strong buy" ratings.

Grab your FREE Eternal Contrarian report!


 




 
Special Offers from Schaeffer's Trading Partners